Efficacy of Tengqi Tongluo Granule in Treating Type 2 Diabetes with Lower Extremity Vascular Disease and Its Influence on Serum Vaspin and RBP4 Levels

OBJECTIVE To observe the curative effect of Tengqi Tongluo granule in treating type 2 diabetes with lower extremity vascular disease with qi deficiency and blood stasis syndrome， and its effect on serum Vaspin and RBP4 levels. METHODS A randomized， parallel controlled clinical study design was adopted. According to traditional Chinese medicine syndrome differentiation of qi deficiency and blood stasis， patients with type 2 diabetic lower extremity vascular disease (DLEAD) were selected and divided into two groups with 30 cases each. The treatment group was treated with Tengqi Tongluo granule orally in addition to the basic treatment (hypoglycemic treatment， antihypertensive treatment， lipid regulation， and anti-platelet aggregation)， while the control group received only the basic treatment. The course lasted for 12 weeks. After treatment， the glucose， lipid metabolism， blood pressure， ankle-brachial index (ABI)， dorsal arterial volume， visceraladiposetissue-derived serine protease inhibitor (Vaspin) and retinol binding protein 4 (RBP4) levels were observed in both groups. RESULTS After treatment， the blood glucose (FBG， PBG， HbAlc) levels of both groups decreased (P<0.05， P<0.01)， but the difference between the groups was not statistically significant (P>0.05). Blood lipids (TC， TG， LDL-C) in the treatment group decreased compared with those before treatment (P<0.05， P<0.01)， HDL-C increased (P>0.05)， and the effect in the treatment group was better than that of the control group (P<0.05). The ABI， dorsal arterial volume and Vaspin level of the two groups increased， while RBP4 level decreased (P<0.05， P<0.01)， and the effects in the treatment group were better than those of the control group (P<0.05). The clinical efficacy in the treatment group was better than that of the control group (P<0.05). CONCLUSION Tengqi Tongluo granule can increase the serum Vaspin level， reduce RBP4 level， improve lipid metabolism， increase ABI and dorsal arterial volume， improve lower limb ischemia symptoms of DLEAD patients， and improve clinical efficacy.